Medidata Solutions, Inc. (NASDAQ:MDSO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) Compensatory Arrangements of Certain Officers

On February 12, 2019, the compensation committee (the “Committee”) of the board of directors of Medidata Solutions, Inc. (the “Company”) approved the following compensatory arrangements for its named executive officers.

2018 Annual Cash Bonuses. The Committee determined the annual cash bonus awards for 2018 for each of the Company’s named executive officers, based on its assessment of achievement of the 2018 performance targets, as follows: Tarek Sherif (Chairman and Chief Executive Officer)—$605,775; Glen de Vries (President)—$605,775; Rouven Bergmann (Chief Financial Officer)— $464,531; Michael Otner (EVP & General Counsel)—$200,475; and Michael Pray (EVP, Global Sales)—$406,181.

2019 Salaries and Bonus Targets. The Committee approved 2019 salaries and target cash bonus amounts for the Company’s named executive officers. The 2019 cash bonuses will be determined by the Committee based on achievement of the following factors: (i) the Chief Executive Officer and President—50% corporate financial performance objectives (revenue and EBITDAO); (ii) the Chief Financial Officer—75% on the company performance objectives and 25% based on individual performance objectives; (iii) EVP & General Counsel—50% on the company performance objectives and 50% based on individual performance objectives; and (iv) EVP, Global Sales —25% on the company performance objectives, 50% based on sales performance objectives (global iACV achievement), and 25% based on individual performance objectives.

The table below sets forth the 2019 salaries and target cash bonus amounts of the Company’s named executive officers:

2019 Equity Awards. The Committee approved equity awards for 2019 to the Amended and Restated 2017 Long-Term Incentive Plan, with 50% of such awards being in the form of shares of restricted stock with time-based vesting, and 50% of such awards being in the form of restricted stock units with performance-based vesting (“PBRSUs”), except for Messrs. Sherif and de Vries who received 35% of such awards in the form of shares of restricted stock with time-based vesting and 65% of such awards in the form of PBRSUs.

The shares of restricted stock will vest annually over a four-year period from grant, 25% on the first anniversary of the grant date and each of the next three annual anniversaries of the grant date (i.e., one-fourth of the shares will vest on each of February 12, 2020, February 12, 2021, February 12, 2022, and February 12, 2023), subject to continued employment with the Company.

Vesting of one half of the PBRSUs will be based on the Company’s achievement of performance goals based on the Company’s Revenue Attainment over a three-year performance period ending December 31, 2021 with the number of shares to be actually earned capped at 250% of the target amount (in accordance with the illustrative models for over-performance and under-performance in comparison to the Company’s targets that were reviewed by the Committee). Vesting of the other half of the PBRSUs will be based on the Company’s total stockholder return (“TSR”) relative to the TSR of companies in the Russell 2000 Index over a three-year performance period ending December31, 2021 with the number of shares to be actually earned capped at 200% of the target amount (in accordance with the illustrative models for over-performance and under-performance in comparison to the Company’s targets that were reviewed by the Committee).

The table below sets forth the 2019 awards of restricted stock and PBRSUs awarded to the following named executive officers:

Supplemental Award to Chief Financial Officer. The Committee approved a supplemental restricted stock award of 7,256 shares of restricted stock to Rouven Bergmann (Chief Financial Officer) to the Amended and Restated 2017 Long-Term Incentive Plan. The shares shall vest annually over a two-year period from grant, 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date (i.e., one-half of the shares will vest on each of February 12, 2020 and February 12, 2021).

About Medidata Solutions, Inc. (NASDAQ:MDSO)

Medidata Solutions Inc. (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Medidata Clinical Cloud provides a platform of technology and data analytics solutions designed to manage activities across clinical development. Its Planning Cloud provides capabilities for study design and planning, enabling customers to make use of resources through planning at the start of trial design and protocol development. Specific functionality supports visibility into the impact of protocol elements on resource and trial endpoints; comparisons to specific industry benchmarks, and analytics to support appropriate grants to investigator sites and automated negotiations with multiple investigator sites. Data Capture Cloud is Medidata’s electronic data capture (EDC) and its management system solution is Medidata Rave.